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Abstract
Objective We developed clinical practice guidelines to
assess the individual risk–benefit profile of androgen
replacement therapy in adult male hypogonadism (HG),
defined by the presence of specific signs and symptoms and
serum testosterone (T) below 12 nmol/L.
Participants The task force consisted of eight clinicians
experienced in treating HG, selected by the Italian Society
of Endocrinology (SIE). The authors received no corporate
funding or remuneration.
Consensus process Consensus was guided by a system-
atic review of controlled trials conducted on men with a
mean T \ 12 nmol/L and by interactive discussions. The
guidelines were reviewed and sequentially approved by the
SIE Guidelines Commission and Executive Committee.
Conclusions We recommend T supplementation (TS) for
adult men with severely reduced T levels (T \ 8 nmol/L)
to improve body composition and sexual function. We
suggest that TS be offered to subjects with T \ 12 nmol/L
to improve glycaemic control, lipid profile, sexual function,
bone mineral density, muscle mass and depressive symp-
toms, once major contraindications have been ruled out.
We suggest that lifestyle changes and other available
interventions (e.g. for erectile dysfunction) be suggested
prior to TS. We suggest that TS should be combined with
currently available treatments for individuals at high risk
for complications, such as those with osteoporosis and/or
metabolic disorders. We recommend against using TS to
improve cardiac outcome and limited mobility. We rec-
ommend against using TS in men with prostate cancer,
unstable cardiovascular conditions or elevated haematocrit.
The task force places a high value on the timely treatment
of younger and middle-aged subjects to prevent the long-
term consequences of hypoandrogenism.
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Methodology and definitions
The recommendations were based exclusively on evidence
from randomised controlled trials (RCTs) of hypogonadal
(HG) subjects, defined by a mean serum testosterone
(T) level below 12 nmol/L. Data from undefined and mixed
populations (eugonadal/HG) or from non-RCTs were ana-
lysed separately and taken into account for the formulation
of values and remarks only.
A number of problems were encountered in the
reviewing process. These pertained to: (a) poor biochemi-
cal and clinical definition of HG in the inclusion criteria;
(b) variability in the age of enrolled subjects, with the
majority of studies performed in middle-aged subjects
(below 75 years); (c) variability in T formulation and dose,
ranging from suboptimal to supra-physiological regimens;
(d) inconsistencies in the definition of comorbidities
(especially for metabolic and cardiovascular disorders);
(e) extreme variability in the duration of treatment (from
4 weeks to 36 months); (f) heterogeneity in the methods
for assessing the primary outcomes; (g) no study primarily
designed to assess cardiovascular or prostate outcomes;
(h) study duration insufficient to address cardiovascular
and prostate safety; (i) unstated or underpowered sample
sizes for either the primary or secondary outcomes for most
studies.
The task force used the following coding system: (1)
indicates a strong recommendation and is associated with
the phrase ‘‘we recommend’’; (2) denotes a weak recom-
mendation and is associated with the phrase ‘‘we suggest.’’
Evidence grading: ØOOO denotes very low quality evi-
dence; ØØOO, low quality; ØØØO, moderate quality; and
ØØØØ, high quality.
The term T replacement therapy has been shortened to
TS. For all recommendations, when not otherwise speci-
fied, HG was defined as mean circulating T levels below
12 nmol/L and the presence of specific signs and symp-
toms, reviewed as potential outcomes: reduced muscle
mass and increased adiposity, altered glucose metabolism,
reduced bone density, low libido, erectile dysfunction,
depression, HIV-related muscle wasting, impaired exer-
cise capacity and anaemia. The formulated recommenda-
tions do not apply to men with mean T values above
12 nmol/L.
Metabolic outcomes
1. We suggest TS for HG subjects with metabolic syn-
drome (MetS) and type 2 diabetes mellitus (T2DM) to
improve glycaemic control (2 ØØOO).
2. We suggest TS for HG subjects to improve lipid profile
(2 ØØOO).
3. We recommend TS to reduce fat mass in HG subjects
(1 ØØØO), and we suggest it for subjects with either
MetS or T2DM (2 ØØOO).
4. We suggest TS to increase lean mass in HG subjects (2
ØØØO) and in those with MetS and T2DM (2 ØØOO).
5. We suggest TS to reduce waist circumference in HG
subjects with MetS and T2DM (2 ØØOO).
Evidence
In HG subjects with MetS and/or T2DM, a limited number
of studies show a tendency towards improved glycaemic
control after TS [1]. However, this trend is not evident in
the general HG population [2–4] and is less evident in
MetS. Conversely, lipid profile, which is tested in a higher
number of studies, seems to improve after TS in all HG
patients [5–8], but this is not so evident in HG subjects with
MetS and/or T2DM [9–11]. Body mass index (BMI) is not
affected by TS in HG subjects with or without metabolic
disorders [3, 9, 10]. A clear-cut decrease in fat body mass
during TS is reported in almost all studies performed in
unselected HG subjects [12] and in the fewer studies per-
formed in HG patients with MetS and/or T2DM [9–11, 13,
14]. Similarly, lean mass increases in all HG patients
receiving TS, although the trend is less evident in patients
with dysmetabolism.
Value
We place an important value on changes to body compo-
sition and metabolic profile in men with unequivocally
reduced T levels.
Remarks
Although the efficacy of TS in improving body composi-
tion has been consistently replicated, the task force remarks
that TS should not be administered as an alternative to
appropriate lifestyle changes [15], which should be pursued
prior to or, in selected cases, alongside TS.
Bone outcomes
6. We suggest TS in men with reduced T levels to
improve, or avoid worsening of, lumbar (2 ØØOO) and
femoral (2 ØOOO) bone mineral density.
Evidence
T has a fundamental role in bone maturation: at the end of
puberty to reach peak bone mass, and during adult life to
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maintain it [16]. HG men have significantly lower bone
mineral densities (BMD) than eugonadal age-matched men
[16]. The prevalence of HG in osteoporotic men, however,
has not been properly assessed. Studies estimate HG in up to
20 % of men with vertebral fractures and 50 % of hip frac-
tures [17]. Some non-placebo-controlled trials and/or trials in
strictly selected non-HG men without other major comor-
bidities are available [18–22]. Taken together, these studies
suggest a positive effect of TS on lumbar spine but not fem-
oral neck BMD. Only two RCTs [23, 24] have been con-
ducted in elderly and clearly HG men (T \ 12 nmol/L), for a
total of 41 subjects [23, 24], treated with intramuscular
T injection. These studies show a significant effect of TS on
femoral BMD, as compared to placebo (?2.7 %) [23, 24],
and a more pronounced effect (?10.2 %) on lumbar BMD,
after 36 months [23]. Another controlled study, performed on
99 HG men with a history of fracture or T-score\–2.0 and
frailty, shows a positive effect of transdermal TS on lumbar
BMD [20]. One non-placebo-controlled RCT study per-
formed on 40 HG men with sexual symptoms and MetS or
T2DM shows a positive relationship between serum T and
BMD increments at both the lumbar and femoral sites after
36 months of T undecanoate treatment [18].
Values
Evidence supporting TS to increase lumbar BMD in HG
men is of low quality. The evidence for femoral BMD is of
very low quality. The task force places a high value on the
long-term (36 months) composite benefits of TS on the
musculoskeletal system, especially when T levels are very
low (\8 nmol/L).
Remarks
Although there is no doubt that T is a key hormone for skeletal
health, a careful diagnosis should be made to characterise
HG, excluding other causes of low BMD and understanding
the relative role of other comorbidities, especially in men
with only a marginal reduction in T levels. No studies report
effects on fracture rates after TS, nor is there any evidence for
the effects of co-treatment with agents with proven anti-
fracture efficacy (e.g. bisphosphonates) and/or vitamin
D/calcium supplementation. Similarly, there is no clear evi-
dence of better results with T injections than with transdermal
administration. For this reason, the task force suggests adding
other pharmacological agents to treat osteoporosis if the
fracture risk is high. Men with a modest or borderline risk of
fracture can be treated with TS alone. In general, the decision
on if and when to add vitamin D, calcium and/or another
specific treatment and which T formulation to use should be
based on an assessment of the risks and benefits for the patient
concerned.
Cardiovascular outcomes
7. We suggest that clinicians exercise caution in giving
T to older men with known cardiovascular disease
(CVD), due to an unclear benefit/risk ratio (2
ØØOO).
8. In patients deserving treatment, we suggest offering
long-acting injectable T esters or transdermal prepa-
rations rather than short-acting T esters, to minimise
the risk of increased haematocrit, a potential cardio-
vascular risk factor (2 ØOOO).
9. We suggest considering TS for middle-aged HG men
with metabolic disorders without known CVD, to
decrease the risk of future cardiovascular events (2
ØOOO).
10. We recommend against TS to improve cardiac
dysfunction in HG men (1 ØOOO).
Evidence
The effects of TS on cardiovascular function, events and
mortality of HG patients are poorly known [25]. Some
studies show beneficial effects on surrogate markers of
cardiovascular health [8, 14, 26]. The few RCTs and sub-
sequent meta-analyses [27–29] suggest that TS in men is
not associated with a consistent CV effect. Most trials rely
on too few adverse events to reach reliable conclusions. A
recent meta-analysis of RCTs [30] identified 27 trials
including 2,994 middle-aged or elderly men (1733
T-treated) with a baseline T level ranging between 7.0 and
20.0 nmol/L, reporting 180 CV-related events, including
CV-related deaths. T treatment increased the risk of CV-
related events (OR 1.54, 95 % CI 1.09–2.18), including
CV-related deaths (OR 1.42; 95 % CI 0.70–2.89), inde-
pendently of baseline T level [30]. However, a more recent
meta-analysis [31] on a much larger population (5,508
men, 3,040 treated with T) confutes these findings, showing
no effect on major cardiovascular events (MACE) and
mortality, and a somewhat CV-protective effect in a sub-
group of HG men with metabolic diseases (OR 0.19 95 %
CI 0.04; 0.85). The major limitation is that none of these
RCTs had CV function or events as the primary or sec-
ondary outcome, and all studies were underpowered to
address this issue. In addition, reporting of adverse events,
bias linked to trial funding [30, 32] and study duration too
short to define CV safety all undermine the validity of the
currently available data. A qualitative review of the trials
seems to suggest that long-acting injectable T esters or
transdermal preparations should be preferred to reduce the
risk of excessive haematocrit increase during TS [28, 33],
although a formal quantitative appraisal is still lacking
[30].
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Values
The recommendation to offer TS to elderly HG men places
a relatively low value on avoiding the burden of TS and its
unclear cardiovascular effects.
Remarks
The risks of treating elderly HG men with TS appear to be
related to age, history of previous CV events and rise in
haematocrit. In younger and middle-aged HG subjects [34],
these risk factors seem, on the whole, to play a minor role
compared to the potential benefits of TS in reducing several
other cardiovascular risk factors.
Sexual function
11. We recommend TS for men with symptoms of low
libido who have markedly reduced T levels
(T \ 8 nmol/L) to improve libido (1 ØØØO); whilst
we suggest TS in men with T levels between 8 and
12 nmol/L (2 ØØØO).
12. We recommend that clinicians offer TS to men with
erectile dysfunction (ED) who have markedly reduced
T levels (T \ 8 nmol/L), to improve erection (1 ØØØO).
13. In men with T levels between 8 and 12 nmol/L and
ED, we suggest considering TS after having tried the
established therapies to recover sexual function (2
ØØØO). In non-responders to phosphodiesterase 5
(PDE5) inhibitors who retain persistently low T levels,
we suggest offering T therapy to improve erectile
function (2 ØØOO).
14. We suggest that clinicians offer TS to men with low
T levels (T \ 12 nmol/L) to improve orgasmic func-
tion (2 ØOOO).
Evidence
Observational data show that sexual complaints, including
ED, are the most common symptoms associated with HG
[35, 36]. Simple correlation, however, does not imply
causation. Several non-placebo-controlled trials are avail-
able [37–40]. The few RCTs contain a sufficiently large
number of treated subjects to draw reliable conclusions
[37–39]. The effects of TS on libido have recently been
meta-analysed [38]. In 17 RCTs, enrolling 1,111 men, TS
determined an improvement in the libido of severely HG
subjects (T \ 8 nmol/L), but not in those with milder
forms of HG. The effects of TS on sex-related erections
were assessed in 1,431 individuals, proving effective only
in men with reduced T levels (\12 nmol/L) [38]. An
inverse relationship between mean T levels at enrolment
and the effect of TS on overall erectile function was
observed. Amongst studies providing International Index
of Erectile Function (IIEF) data, TS resulted in a weighted
mean improvement of about 40 % (range: 22–79 %), cor-
responding to a weighted mean delta of 4 ± 2 points in the
IIEF-5 score (range: 3–8) [39]. Clinical studies document
that T not only controls libido and erectile function but is
also involved in the regulation of the orgasmic component
of male ejaculatory reflex, acting both centrally and
peripherally [38]. Ten studies enrolling 677 patients
investigated the effect of TS on orgasm, confirming the
relationship between baseline mean T levels and the effect
size on TS orgasmic function.
Values
There is enough evidence to support the use of TS for men
with unequivocally low T levels and sexual complaints.
The task force places a high value on the composite ben-
efits of treating young HG men and a lower value on the
treatment of older men, due to the uncertainty of long-term
CV safety.
Remarks
The decision as to whether or when to treat HG men to
improve sexual symptoms remains problematic. ED gen-
erally has a multifactorial aetiology; vascular factors are
predominant amongst the comorbidities and hamper the
beneficial effects of TS. In young HG subjects, TS is often
sufficient to improve sexual function. In older men, the low
T level may be the consequence rather than the cause of ED
[41]. A large number of HG ED patients could be safely
treated with PDE5-I monotherapy and TS could be offered
as an add-on treatment only for those with persistently low
T levels, [39, 41]. The decision to start TS in older HG men
depends on the patient’s individual benefit/risk ratio.
Other outcomes
15. We suggest that clinicians offer TS to HG men with
depression to improve depressive symptoms (2 ØØOO),
in addition to the established therapies for depression.
16. We suggest that clinicians offer TS to HG men and
HIV/AIDS to improve lean mass (2 ØOOO).
17. We suggest against the use of TS to improve exercise
capacity in individuals with chronic obstructive
pulmonary disease (COPD) and frail men (2 ØOOO)
or to improve quality of life (QoL) in subjects with
end-stage renal diseases (ESRD) or undergoing
glucocorticoid or opioid therapy (2 ØOOO).
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Evidence
Depression
Depressed mood is a symptom often associated with HG,
suggesting that androgen deficiency contributes to mood
disorders [1, 42, 43]. It is unclear, however, whether low
T levels are correlated with the development of major
depressive disorder [42]. The relationship between low
T and the incidence of clinical depression is still unclear,
especially in elderly men [42]. Few RCTs have evaluated
the effect of TS on depressive symptoms (Table 1). Zarrouf
et al. [43] evaluated the impact of TS on major depressive
disorder according to DSM-IV-defined criteria in seven
trials including 355 patients with an age range of
18–70 years. They found a positive effect of TS on Ham-
ilton-D depression rating scale scores in depressed patients
with T \ 10 nmol/L and in patients with HIV/AIDS.
Similar results are reported in a more up-to-date meta-
analysis [44].
HIV/AIDS
The prevalence of low T levels in HIV-infected men ranges
from 20 to 25 % [1, 45, 46]. Low T is closely correlated
with weight loss, progression to AIDS, wasting syndrome,
depression and loss of muscle mass and exercise capacity
[45]. The mechanisms underlying the association between
HG and HIV have been reviewed elsewhere [45]. In a
recent meta-analysis of the available RCTs in HIV-positive
men, including 344 individuals, Corona et al. [1] found that
TS improved lean mass over placebo. However, results
from these trials were heterogeneous and limited by the
small sample size. In particular, when more selective cri-
teria for HG were applied (T \ 12 nmol/L) only two trials
were eligible (Table 1).
Other diseases
Current guidelines [47, 48] suggest that clinicians consider
case detection through measuring total T levels in men with
certain clinical conditions (including CPOD, ESRD or in
those treated with opioid or glucocorticoid therapy).
However, the limited evidence from RCTs in these par-
ticular populations does not permit any final conclusions to
be drawn about the specific role of TS in these subjects or
in frailty [1].
Values
The task force places a relatively high value on the rec-
ommendation to offer TS to HG men with major depressive
disorders and in those resistant to the use of common
antidepressants, and a high value on TS in HIV-infected
men with HG to prevent and/or combat wasting syndrome
by improving lean body mass.
Remark
It should be recognised that evidence for the role of TS in
depressed or HIV men is limited, considering both the
number of patients enrolled and the follow-up. Further
information on the long-term benefits and adverse effects
of T use in these subjects is therefore required. The out-
comes of TS in other disorders, including CPOD and
ESRD, in frail subjects or in those treated with glucocor-
ticoids or opioids are the same as for patients with classic
androgen deficiency [47, 48].
The prostate
18. We recommend against limiting TS in HG men with
the aim of preventing a new incidence of prostate
cancer (PCa) (1 ØØØO).
19. We recommend against using TS in HG men with PCa
and we recommend against using TS, without further
urological investigation, when total PSA is above the
normal or in the presence of an abnormal digital rectal
examination (palpable nodule) (1 ØØOO).
20. We suggest considering TS in men with signs and
symptoms of HG after at least 12 months of clinical
and biochemical cure following radical prostatectomy
for PCa, but only under strict monitoring (2 ØOOO).
21. We suggest against using TS in HG men with an overt
urinary tract obstruction due to benign prostatic
enlargement (BPE) (2 ØOOO).
22. We recommend long-term follow-up in men with
markedly low (\8 nmol/L) or borderline (8–12 nmol/
L) T levels and symptoms of HG who are given TS;
this should be stricter in the first year [3, 6 (or 9
according to the clinician’s judgement) and
12 months] and at least annually thereafter, with
measurement of total (and free) PSA and evaluation
of prostate volume by digital rectal examination (1
ØØØO) or trans-rectal ultrasound.
Evidence
There are no data suggesting that TS is associated with an
increased risk of prostate cancer [49]. Observational data on
[1,100 subjects revealed that about 64 % of HG men
treated with T do not show an increase in PSA. Six RCTs
found that TS increases PSA values [6, 23, 50–53], but
only in two was the increase significant [52, 53]. The
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Table 1 Evidence from available RCTs in support of the provided recommendations
Characteristics of study
population
Outcome Number of
available
RCTs
Number of
enrolled
subjects
Mean duration
of RCT months
(range)
Summary of
observed
effects
Body composition (for additional data see references [1–15])
MetS or T2DM Waist circumference 6 701 10.7 [2.7–24] ;
Metabolically unclassified Waist circumference 3 172 6.6 [3–11] $
MetS or T2DM BMI 8 773 8.8 [2.7–24] $
Metabolically unclassified BMI 5 307 11.2 [3–24] $
MetS or T2DM Body fat 5 379 10.7 [3–24] ;
Metabolically unclassified Body fat 10 1,513 11 [3–36] ;
MetS or T2DM Body lean 4 174 10.4 [2.7–24] :
Metabolically unclassified Body lean 9 1,491 10.8 [3–36] :
Metabolism (for additional data see references [1–15])
MetS or T2DM Glycaemia 7 725 9.6 [2.7–24] $
Metabolically unclassified Glycaemia 5 324 9.4 [3–24] $
MetS or T2DM Glycated haemoglobin 6 555 10 [2.7–24] ;
MetS or T2DM Total cholesterol 7 725 9.6 [2.7–24] $
Metabolically unclassified Total cholesterol 9 490 11.7 [1–36] ;
MetS or T2DM HDL cholesterol 7 725 9.6 [2.7–24] $
Metabolically unclassified HDL cholesterol 10 546 13 [1–36] $
MetS or T2DM LDL cholesterol 5 633 6.2 [2.7–12] $
Metabolically unclassified LDL cholesterol 8 464 15.5 [1–36] ;
MetS or T2DM Triglycerides 7 725 9.6 [2.7–24] $
Metabolically unclassified Triglycerides 8 380 8.7 [1–36] ;
Bone density (for additional data see references [16–24])
Healthy men Lumbar and femoral bone mineral density 2 41 12–36 : lumbar
: femoral
History of fracture or
T-score \-2.0 and frailty
Lumbar, femoral and radius bone mineral
density
1 53 12 : lumbar
; radius
Sexual function (for additional data see references [35–41])
Young to middle-aged men with
sexual dysfunction
Libido 17 1,111 3 months (1–12) :
(if T \ 8
nM/L)
Young to middle-aged men with
sexual dysfunction
Sexual related erections 24 1,431 3 months (1–12) :
(if T \ 12
nM/L)
Young to middle-aged men with
sexual dysfunction
Orgasmic function 10 677 3 months (1–12) :
(if T \ 12
nM/L)
Prostate gland (for additional data see references [6, 9, 10, 23, 49–55])
Middle-aged to aged men with
hypogonadism
Serum PSA 6 286 16.5 [3–36] $
Men with hypogonadism
(unspecified age or wide age
range)
Serum PSA 10 461 6 [3–12] $
Middle-aged men with
hypogonadism
Prostate volume or prostate-related
symptoms (DRE and evaluation of low
urinary tract function)
7 256 10 [3–36] $
Men with hypogonadism and
prostate cancer
Serum PSA, prostate volume or symptoms
(urine flow rate, voiding symptoms,
prostate biopsy)
1 21 6 $
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majority of patients had a clinical condition of HG with
markedly reduced T levels (\ 8 nmol/L) or T levels
between 8 and 12 nmol/L and symptoms of HG. A smaller
proportion of patients showed comorbidities such as T2DM
or MetS [9, 10, 54]. Only 23 % of 250 patients had an
increase in prostate volume (assessed by digital rectal
examination or prostate ultrasound scan) [6, 23, 55], whilst
in the remaining it was within the normal range.
Values
The task force places high value on the recommendation
that TS, when appropriately given to HG men, has no
carcinogenic effect on an otherwise unaffected prostate
gland.
Remarks
The effects of TS on the prostate gland are not such as to
advise limiting its use, given its potential benefits on var-
ious cardiovascular, metabolic and sexual outcomes. TS
may therefore be considered safe for the prostate gland in
all patients without clinically evident PCa, as long as
accurate screening is performed beforehand and adequate
follow-up is performed.
Adverse effects
23. We recommend against using TS in patients with
haematocrit higher than the upper limit of the normal
range (1 ØØØO).
24. We recommend monitoring blood parameters to avoid
critical elevation of haematocrit, especially when
using intramuscular T preparations (1 ØØOO).
25. We suggest against using 17-alpha-alkylated deriva-
tives of T. The available T preparations do not have
negative effects on liver function [48] (2 ØØOO).
26. We recommend against starting TS in HG patients
who are attempting to father a child (1 ØØØO).
27. We suggest against using TS in men with a known
history of obstructive sleep apnoea (2 ØOOO).
Evidence
TS induces a dose-dependent increase in haematocrit
within 1 month [27, 28]. This effect is higher with short-
acting than with long-acting, injectable T esters or trans-
dermal preparations [33]. The increase is caused by both
erythropoietin and the direct effect of T on bone marrow
[56]. Fernandez-Balselles et al. [28] showed that T-treated
men had a 3.15-times higher risk of developing erythro-
cytosis compared to placebo-treated controls, especially
with intramuscular T formulations. However, this rarely
results in thrombosis, as demonstrated by meta-analyses
considering all cardiovascular events [1, 27, 28]. Never-
theless, frequent monitoring is necessary to avoid critically
elevated levels, with 54 % considered the cut-off for sus-
pension [48]. Polycythaemia reverts to baseline after
T withdrawal. RCTs rarely report increased haematocrit as
an adverse event of TS (Table 1). Some studies report a
significant haematocrit increase with intramuscular TS [10,
57–59]. However, only a small number of HG patients
were considered and haematocrit was not the primary
endpoint.
The negative effect of TS on liver function is only
associated with the use of alkylated 17a T formulations,
which have already been withdrawn from the market.
Long-term studies showing the liver effects of the currently
used T preparations are lacking.
TS down-regulates the hypothalamus–pituitary axis,
depressing LH and FSH and further decreasing endogenous
T synthesis, thereby inhibiting sperm production [48].
Androgens have been actively studied for potential use in
male hormonal contraception. The negative effect of T on
fertility is transient and fully reversible, with a predictable
course [60].
Few studies have considered the effects of TS on
obstructive sleep apnoea syndrome (OSAS) in patients with
Table 1 continued
Characteristics of study
population
Outcome Number of
available
RCTs
Number of
enrolled
subjects
Mean duration
of RCT months
(range)
Summary of
observed
effects
Men with hypogonadism and
diabetes mellitus type 2 or
Metabolic syndrome
Serum PSA, Prostate volume, IPSS 3 239 10 [7–12] $
Other parameters (for additional data see references [1, 42–48]
Major depression Improvement of depressive symptoms 5 210 7.6 (6–12) :
HIV/AIDS Improvement of lean mass 2 82 21 (16–26) :
$ no modification or conflicting results after TS; : increased during TS; ; decreased during TS
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HG. One randomised, placebo-controlled study showed
that intramuscular T undecanoate acutely worsened sleep
hypoxaemia in patients with obesity and OSAS. An open-
label study on five HG men reported worsened OSAS with
intramuscular T enanthate [61]. However, Snyder et al. [62]
did not find any change in respiratory distress index in 108
HG men treated with transdermal T for 36 months.
Few randomised, placebo-controlled trials indicate
which adverse events resulted in patients dropping out of
the study. In men treated with transdermal T erythema,
pruritus and nasopharyngitis occurred in about 45 % of
patients in both the study and control groups [10]. Trans-
dermal approaches might increase the risk of transfer of
T to others during close skin contact, although this was
found unlikely in a randomised controlled study [63].
Values
There is enough evidence to recommend avoiding the use of
TS in men with elevated haematocrit levels. To prevent this
adverse effect, the task force gives a high value to monitoring
haematocrit during treatment. Similarly, a high value is given
to the negative effect of T treatment in patients requiring
fertility. Few RCTs have evaluated TS in men with OSAS.
Remarks
There is no clear haematocrit threshold above which TS
should be avoided or suspended, therefore, continuous
monitoring of the individual risk profile (e.g. dehydration,
hypercoagulability, smoking) is mandatory during T treat-
ment. At the same time, any wish to start a family should
be considered before starting TS. Finally, OSAS is a
complex disease and generally has a multifactorial aetiol-
ogy. In this context, the effect of TS is far from being
understood and the decision to start the therapy depends on
a careful evaluation of the patient’s characteristics.
Conflict of interest All authors certify that they have no actual or
potential conflict of interest in relation to this article.
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